Objective:

To investigate the role of IGFBP-6 in regulating progesterone receptor signaling and its impact on cell cycle progression in breast cancer cells.

Approach:

• Proteomic Analysis: Conducted in progesterone-treated T47D breast cancer cells following siRNA-mediated knockdown of IGFBP-6.
• Cell Cycle Analysis: Examined the effects of IGFBP-6 and SH2D4A knockdown on cell cycle progression and protein expression.
• Survival Analysis: Utilized Kaplan-Meier survival plots to assess the impact of SH2D4A expression on patient outcomes in luminal A breast cancers.

Key Findings:

• IGFBP-6 is induced by progesterone and regulates progesterone receptor signaling.
• Knockdown of IGFBP-6 or SH2D4A leads to cell cycle arrest in G1 phase.
• SH2D4A expression is associated with improved survival outcomes in luminal A breast cancer patients.
• Progesterone treatment resulted in downregulation of 29 proteins and upregulation of 14 proteins in IGFBP-6-low cells.

Interpretation:

The study identifies a pathway involving progesterone, IGFBP-6, and SH2D4A related to cell cycle progression in breast cancer cells.

Limitations:

• The study primarily focuses on T47D breast cancer cells, which may limit the generalizability of the findings to other breast cancer types.
• Further research is needed to explore the clinical implications of the identified pathway.

Conclusion:

The results indicate a regulatory mechanism involving IGFBP-6 and SH2D4A in breast cancer cell cycle progression in response to progesterone.